A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer-Reference-Cited by-同舟云学术

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer

Published:2016-07 Issue:27 Volume:95 Page:e3845
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Sciarra Alessandro,Fasulo Andrea,Ciardi Antonio,Petrangeli Elisa,Gentilucci Alessandro,Maggi Martina,Innocenzi Michele,Pierella Federico,Gentile Vincenzo,Salciccia Stefano,Cattarino Susanna

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference19 articles.

1. Prostate cancer guidelines.;Mottet;European Urological Association EAU guidelines,2015

2. Bench-to bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer;Rick;Urol Oncol,2015

3. Gonadotropin releasing hormone: an update review of the antagonists versus agonists;Van poppel;Int J Urol,2012

4. Prostate cancer guidelines.;Mohler;NCCN guidelines,2015

5. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement;Moher;Plos Med,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk;Clinical Pharmacology in Drug Development;2024-05-17

2. Big peptide drugs in a small molecule world;Frontiers in Chemistry;2023-12-07

3. Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses;Cancers;2023-12-06

4. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States;PharmacoEconomics;2023-11-07

5. Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer;Cureus;2023-06-21